Arcturus Therapeutics Holdings Management
Management criteria checks 2/4
Arcturus Therapeutics Holdings' CEO is Joe Payne, appointed in Mar 2013, has a tenure of 11.25 years. total yearly compensation is $4.89M, comprised of 14.3% salary and 85.7% bonuses, including company stock and options. directly owns 5.5% of the company’s shares, worth $57.44M. The average tenure of the management team and the board of directors is 1.1 years and 5.4 years respectively.
Key information
Joe Payne
Chief executive officer
US$4.9m
Total compensation
| CEO salary percentage | 14.3% |
| CEO tenure | 11.3yrs |
| CEO ownership | 5.5% |
| Management average tenure | 1.1yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat
May 11Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space
Apr 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$107m |
| Dec 31 2023 | US$5m | US$698k | -US$30m |
| Sep 30 2023 | n/a | n/a | US$99m |
| Jun 30 2023 | n/a | n/a | US$80m |
| Mar 31 2023 | n/a | n/a | US$111m |
| Dec 31 2022 | US$6m | US$630k | US$9m |
| Sep 30 2022 | n/a | n/a | -US$147m |
| Jun 30 2022 | n/a | n/a | -US$165m |
| Mar 31 2022 | n/a | n/a | -US$198m |
| Dec 31 2021 | US$960k | US$600k | -US$204m |
| Sep 30 2021 | n/a | n/a | -US$196m |
| Jun 30 2021 | n/a | n/a | -US$163m |
| Mar 31 2021 | n/a | n/a | -US$119m |
| Dec 31 2020 | US$13m | US$500k | -US$72m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$29m |
| Dec 31 2019 | US$1m | US$450k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | US$3m | US$425k | -US$22m |
| Sep 30 2018 | n/a | n/a | -US$26m |
| Jun 30 2018 | n/a | n/a | -US$25m |
| Mar 31 2018 | n/a | n/a | -US$16m |
| Dec 31 2017 | US$449k | US$384k | -US$11m |
Compensation vs Market: Joe's total compensation ($USD4.89M) is above average for companies of similar size in the US market ($USD3.42M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
CEO
Joe Payne (52 yo)
11.3yrs
Tenure
US$4,892,500
Compensation
Mr. Joseph E. Payne, also known as Joe, M.Sc. has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. H...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.3yrs | US$4.89m | 5.5% $ 57.4m | |
| Founder | 11.4yrs | US$3.18m | 1.76% $ 18.4m | |
| CFO & Director | 5.8yrs | US$2.18m | 1% $ 10.5m | |
| Chief Legal Officer | 3.8yrs | US$2.10m | 0% $ 0 | |
| Vice President and Head of IR/PR & Marketing | no data | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Chief Business Officer | 5.8yrs | no data | no data | |
| Chief Medical Officer | 1.1yrs | no data | no data | |
| Chief Development Officer | 1.1yrs | no data | no data | |
| Chief Strategy Officer | less than a year | no data | no data | |
| Chief Regulatory Officer | less than a year | no data | no data | |
| Controller | less than a year | no data | no data |
1.1yrs
Average Tenure
56yo
Average Age
Experienced Management: ARCT's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.3yrs | US$4.89m | 5.5% $ 57.4m | |
| CFO & Director | 4.8yrs | US$2.18m | 1% $ 10.5m | |
| Independent Chairman of the Board | 6.1yrs | US$328.00k | 0.35% $ 3.7m | |
| Independent Director | 4.8yrs | US$325.50k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$330.50k | 0.037% $ 388.1k | |
| Independent Director | 6.1yrs | US$318.00k | 0.093% $ 968.0k | |
| Member of the Vaccine Platform Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.6yrs | no data | no data | |
| Member of the Vaccine Platform Scientific Advisory Board | 3.9yrs | no data | no data | |
| Strategic Clinical Advisor & Member of Scientific Advisory Board | 2.3yrs | US$644.00k | no data | |
| Member of the Vaccine Platform Scientific Advisory Board | 3.9yrs | no data | no data |
5.4yrs
Average Tenure
65yo
Average Age
Experienced Board: ARCT's board of directors are considered experienced (5.4 years average tenure).